|
시장보고서
상품코드
2039094
진행성 핵상마비 치료 시장 : 약물 유형별, 유통 채널별, 지역별Progressive Supranuclear Palsy Treatment Market, By Drug Type, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
진행성 핵상마비(PSP) 치료 시장은 2026년에 3억 1,300만 달러로 추정되며, 2033년까지 6억 8,900만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 12.2%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 3억 1,300만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 12.20% | 2033년 시장 규모 예측: | 6억 8,900만 달러 |
진행성 핵상마비(PSP)는 파킨슨병과 유사한 신경퇴행성 질환입니다. 이 질환은 뇌 내 신경세포의 손상으로 인해 발생합니다. 이 질환의 흔한 증상 중 하나는 눈을 제대로 주시하거나 움직일 수 없으며, 환자는 시야가 흐려지는 듯한 감각을 경험할 수 있습니다. 이는 신체의 움직임, 보행(즉, 걸음걸이와 균형), 언어, 삼킴, 시각, 기분과 행동, 그리고 사고에 영향을 미치는 희귀한 뇌질환입니다.
시장 역학
진행성 상핵성 마비(PSP)의 발병률 증가가 진행성 상핵성 마비 치료제 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, 미국 국립신경질환 및 뇌졸중 연구소(NINDS)가 2020년 7월에 발표한 기사에 따르면, 전 세계적으로 인구 10만 명당 약 3-6명이 진행성 핵상마비를 앓고 있으며, 미국에서는 약 2만 명이 이 질환을 앓고 있는 것으로 보고되고 있습니다.
그러나 진행성 핵상마비의 식별 및 진단이 불충분하다는 점이 시장 성장을 저해할 것으로 예상됩니다. 예를 들어, 미국 국립신경질환 및 뇌졸중 연구소(NINDS)가 2020년 7월에 발표한 기사에 따르면, 현재 진행성 핵상마비를 확정적으로 진단할 수 있는 특정 임상 검사나 영상 진단법은 존재하지 않는다고 합니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진요인, 저해요인, 기회, 신약 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 이 보고서는 회사 개요, 재무 실적, 제품 포트폴리오, 시장 입지, 유통 전략, 주요 개발, 전략 및 향후 계획과 같은 매개 변수를 기반으로 세계 진행성 핵상마비 치료 시장의 주요 기업 프로파일을 제공합니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 의약품 출시, 약물군 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 세계 진행성 핵상마비 치료 시장 보고서는 투자자, 공급업체, 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 진행성 핵상마비 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 진행성 핵상마비 치료 시장 : 약물 유형별, 2021-2033년
제5장 진행성 핵상마비 치료 시장 : 유통 채널별, 2021-2033년
제6장 진행성 핵상마비 치료 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSM 26.06.04Progressive Supranuclear Palsy Treatment Market is estimated to be valued at USD 313 Mn in 2026 and is expected to reach USD 689 Mn by 2033, growing at a compound annual growth rate (CAGR) of 12.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 313 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 12.20% | 2033 Value Projection: | USD 689 Mn |
Progressive supranuclear palsy (PSP) is a neurodegenerative disease alike Parkinson's disease. The disease results from damage to nerve cells in the brain. One of the common symptomof the disease include inability to aim and move the eyes properly, where individuals may experience as blurring of vision. It is a rare brain disorder that affects body movement, control of walking i.e. gait and balance, speech, swallowing, vision, mood and behavior, and thinking.
Market Dynamics
Rising incidence of progressive supranuclear palsy (PSP) is expected to drive progressive supranuclear palsy treatment market growth. For instance, according to the National Institute of Neurological Disorders and Stroke, an article published in July 2020, reports that about 3-6 in every 100,000 people have progressive supranuclear palsy worldwide, and around 20,000 U.S. populace are suffering from progressive supranuclear palsy.
However, lack of identification or diagnosis of progressive supranuclear palsy are expected to hinder the market growth. For instance, according to the National Institute of Neurological Disorders and Stroke, an article published in July 2020, states that currently there are no specific laboratory tests or imaging approaches are definitively diagnose progressive supranuclear palsy.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global progressive supranuclear palsy treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are AbbVie Inc., Acorda Therapeutics Inc., Biogen Inc., Bristol-Myers Squibb Co., Merck & Co. Inc., UCB Biopharma, AlzProtect, Asceneuron Therapeutics, TauRx Pharmaceuticals, GlaxoSmithKline PLC, Novartis AG, and Teva Pharmaceutical Industries Ltd. among others
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global progressive supranuclear palsy treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global progressive supranuclear palsy treatment market.
Market Segmentation
- By Drug Type (Revenue, USD Mn, 2021-2033)
- Dopamine
- Anticholinergic Agents
- Tricyclic Antidepressants
- Others
- By Distribution Channel (Revenue, USD Mn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region (Revenue, USD Mn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- AbbVie Inc.
- Acorda Therapeutics Inc.
- Biogen Inc.
- Bristol-Myers Squibb Co.
- Merck & Co. Inc.
- UCB Biopharma
- AlzProtect
- Asceneuron Therapeutics
- TauRx Pharmaceuticals
- GlaxoSmithKline PLC
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Progressive Supranuclear Palsy Treatment Market, By Drug Type, 2021 - 2033, (USD Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Dopamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Anticholinergic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Tricyclic Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
5. Progressive Supranuclear Palsy Treatment Market, By Distribution Channel, 2021 - 2033, (USD Million)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
6. Progressive Supranuclear Palsy Treatment Market, By Region, 2021 - 2033, (USD Million)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Million)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Acorda Therapeutics Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Biogen Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Bristol-Myers Squibb Co.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Merck & Co. Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- UCB Biopharma
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- AlzProtect
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Asceneuron Therapeutics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- TauRx Pharmaceuticals
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
8. Section
- References
- Research Methodology
- About Us
